🇺🇸 FDA
Pipeline program

GRAALL2014

Phase 2 other active

Quick answer

GRAALL2014 for Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years) is a Phase 2 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
Phase
Phase 2
Modality
other
Status
active

Clinical trials